Description of the medicine: Lidase (Lydazum)
A drug containing the enzyme hyaluronidase.
Similar drugs are produced abroad under the names: Alidase, Hyalase, Hyalidase, Hyaluronidasum, Hyasa, Hyason, Hylase, Invasinum, Spredine, Widase, etc.
Slightly yellow or golden yellow porous mass. Easily soluble in water.
Hyaluronidase is an enzyme whose specific substrate is hyaluronic acid. The latter is a mucopolysaccharide, which includes acetylglucosamine and glucuronic acid. Hyaluronic acid has a high viscosity; its biological significance lies mainly in the fact that it is a cementing substance of connective tissue.
Hyaluronidase, or the "distribution factor", causes the breakdown of hyaluronic acid to glucosamine glucuronic acid and thereby reduces its viscosity. Hyaluronidase causes an increase in tissue permeability and facilitates the movement of fluids in interstitial spaces.
Hyaluronidase is found in various tissues of the body. The ratio of the system "hyaluronic acid - hyaluronidase" is largely regulated by tissue permeability. The anti-inflammatory effect of various drugs (salicylates, pyrazolone derivatives, ACTH, glucocorticoids, steroids, etc.) is partially associated with their ability to reduce the activity of hyaluronidase. On the contrary, the effect of certain substances that cause an increase in permeability (for example, bee and snake venom) is due in part to the presence of hyaluronidase in them.
The action of hyalurocidase is reversible. With a decrease in its concentration, the viscosity of hyaluronic acid is restored. Thus, hyaluronidase can be used to temporarily reduce the viscosity of hyaluronic acid.
Preparations containing hyaluronidase (lidase and ronidase) are obtained from the testes of cattle.
Lidase is a specially purified preparation suitable for parenteral (subcutaneous, intramuscular) and inhalation use.
Lyophilized powder or porous mass, or porous mass compacted into a tablet, light color with a beige tint. Easily soluble in water.
The activity of the drug is expressed in arbitrary units (UE).
Available in bottles sealed with rubber stoppers with aluminum caps containing 64 UE of sterile substance.
For injection, the contents of the vial are dissolved in 1 ml of an isotonic sodium chloride solution or in 1 ml of a 0.5% novocaine solution, for inhalations - in 5 ml of an isotonic sodium chloride solution.
The main indications for the use of lidase are joint contractures, scars after burns and operations, ankylosing spondylitis, hematomas, and others. A lidase solution (1 ml) is injected in these cases near the site of the lesion under the skin or under scarred tissues. Injections are performed daily or every other day; the course of treatment consists of 6 - 10 - 15 or more injections.